Pathos
PrivateLast Round
Series E
Aug 4, 2026
Est. Valuation
$3B
Total Funding Raised
$467M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Pathos is a clinical-stage biotechnology company that utilizes an AI-enabled drug discovery platform to accelerate the development of precision oncology therapeutics.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical AI
Business Model
B2B
Customer Profile
Services & Consulting, Data as a Service
AI Layer
Foundation
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Pathos Comparables
Compare Pathos with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Valo Health | 83% | |
| Insilico Medicine | 81% | |
| Insitro | 81% |
Pathos Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series E | Aug 4, 2026 | ||||
| Series D | May 15, 2025 | ||||
| Series C | Oct 29, 2024 | ||||
| Series B | Mar 2, 2023 | ||||
| Series A | Jul 1, 2021 |
Key People
Founding team and executive leadership
Pathos Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Builders VC | Series C, Series B, Series A |
| Lightbank | Series C, Series B, Series A |
| New Enterprise Associates | Series B, Series A, Series C |
| Revolution Ventures | Series C |
| Revolution Growth | Series C, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 4, 2026
$300M round at $3B valuation.
- Apr 1, 2026
AI drug development platform Foundry is now live and in production.
Recent news
Latest coverage and updates
- is_developingAug 6, 2026
Pathos is developing JSKN016 on Aug 3rd '26.
- partners_withAug 4, 2026
Pathos AI, Inc. was planning to partner with AstraZeneca PLC on Aug 3rd '26.
- partners_withAug 4, 2026
Pathos partnered with Alphamab on Aug 1st '26.
- is_developingAug 3, 2026
Pathos is developing oncology models using de-identified clinical, genomic and imaging data.
Pathos Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Pathos's valuation, stock price, and market status.
Is Pathos a public or private company?
Pathos is a private company.
What is the current stock price of Pathos?
Pathos is a private company with no public stock price. No recent secondary market data is available.
How much is Pathos worth (valuation)?
Pathos's valuation is estimated at $1.6B based on funding round data.
Can I buy Pathos stock?
Pathos shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Pathos's last funding round?
Pathos's most recent funding round was Series D on May 15, 2025.
Who are the main investors in Pathos?
Key investors in Pathos include New Enterprise Associates (NEA).
Will Pathos IPO soon?
No public IPO plans have been announced for Pathos.
How can I track Pathos secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Pathos's secondary market activity and sign up for updates.